ArticleCurrent therapeutic research, clinical and experimental2026
The Berberine Derivative BBR684 Inhibits VDAC Oligomerization to Suppress Ferroptosis in Acute Kidney Injury.
Article in Current therapeutic research, clinical and experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ferroptosis is an iron-dependent form of programmed cell death driven by lipid peroxidation and is implicated in acute kidney injury (AKI). Objective: Here, we investigated the therapeutic potential of BBR684, a derivative of berberine, in suppressing ferroptosis and alleviating AKI. Methods: The anti-ferroptotic activity in HK-2 cells was assessed by Western blot, flow cytometry, and immunofluorescence. Renal fibrosis and the expression of related proteins were evaluated using Masson staining, PI staining, and immunohistochemistry. Results: Our findings suggest that BBR684 exhibits superior efficacy compared to berberine in reversing erastin-induced ferroptosis in HK-2 cells. Mechanistically, BBR684 confers cytoprotection by restoring glutathione (GSH) levels and glutathione peroxidase 4 (GPX4) expression, thereby reducing oxidative stress. Moreover, BBR684 directly binds to the voltage-dependent anion channel (VDAC), inhibiting its oligomerization and transport activity. This interaction reduces intracellular reactive oxygen species (ROS) and calcium (Ca2+) accumulation, preserves mitochondrial integrity, and ultimately inhibits ferroptosis. In vivo, BBR684 significantly alleviated folic acid (FA)-induced acute kidney injury (AKI) in mice, as evidenced by decreased serum creatinine and blood urea nitrogen levels, along with improved renal histopathology. Additionally, BBR684 diminishes inflammatory responses and lipid peroxidation, reinforcing its renoprotective effects. Collectively, these results identify BBR684 as a potent ferroptosis inhibitor with therapeutic potential for AKI and other ferroptosis-related diseases. Conclusions: BBR684 inhibits VDAC oligomerization to suppress ferroptosis in acute kidney injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.